What Happened?
Shares of clinical research company IQVIA (NYSE: IQV) jumped 3% in the afternoon session on continued positive momentum after the company reported better-than-expected second-quarter earnings and received several price target increases from Wall Street analysts.
The health information technology and clinical research company announced quarterly earnings per share of $2.81 on revenue of $4.02 billion, beating analyst consensus estimates. The company's revenue grew 5.3% compared to the same period last year, reflecting strong demand in the pharmaceutical and biotech sectors.
Following the strong report, several investment firms raised their price targets on the stock. Jefferies lifted its target to $195, citing improved bookings and strong performance in the company's Technology & Analytics Solutions segment. Similarly, Robert W. Baird increased its target to $196, and Truist Securities raised its target to $235, maintaining a Buy rating. These upward revisions from analysts signaled growing confidence in IQVIA's growth prospects.
After the initial pop the shares cooled down to $193.63, up 3.3% from previous close.
Is now the time to buy IQVIA? Access our full analysis report here, it’s free.
What Is The Market Telling Us
IQVIA’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 1 day ago when the stock gained 15.9% on the news that the company reported second-quarter financial results that beat Wall Street expectations and raised its full-year profit guidance.
The company announced second-quarter revenue of $4.02 billion, which surpassed analyst estimates of $3.96 billion. Adjusted earnings per share (EPS), a key measure of profitability, came in at $2.81, which was also ahead of the consensus forecast of $2.77. The strong performance was driven by solid growth across its business segments, with the Technology & Analytics Solutions division seeing an 8.9% revenue increase.
Looking ahead, IQVIA updated its full-year 2025 guidance. It slightly raised its forecast for adjusted EPS to a range of $11.75 to $12.05. The company also reaffirmed its full-year revenue projection, expecting between $16.1 billion and $16.3 billion. The positive results and optimistic outlook appeared to boost investor confidence, signaling robust demand for its clinical research and data analytics services.
IQVIA is down 0.8% since the beginning of the year, and at $193.63 per share, it is trading 23% below its 52-week high of $251.55 from August 2024. Investors who bought $1,000 worth of IQVIA’s shares 5 years ago would now be looking at an investment worth $1,199.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
